PDS Biotechnology (NASDAQ:PDSB) Trading Down 5.3% – Here’s What Happened

PDS Biotechnology Corporation (NASDAQ:PDSB) fell 5.3% during trading on Wednesday . The company traded as low as $0.90 and last traded at $0.9090. Approximately 659,799 shares changed hands during mid-day trading, a decline of 34% from the average session volume of 999,362 shares. The stock had previously closed at $0.96.

Wall Street Analyst Weigh In

Several research analysts have weighed in on PDSB shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Tuesday, April 21st. Wall Street Zen raised shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of PDS Biotechnology in a research note on Wednesday, April 15th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, PDS Biotechnology presently has an average rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Stock Performance

The company has a debt-to-equity ratio of 2.73, a current ratio of 2.26 and a quick ratio of 2.26. The company has a market capitalization of $53.31 million, a price-to-earnings ratio of -1.43 and a beta of 1.57. The business’s 50-day moving average price is $1.12 and its two-hundred day moving average price is $0.90.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. Research analysts predict that PDS Biotechnology Corporation will post -0.52 earnings per share for the current year.

Institutional Trading of PDS Biotechnology

Institutional investors have recently modified their holdings of the stock. Armistice Capital LLC acquired a new stake in shares of PDS Biotechnology during the 4th quarter worth $2,182,000. Squarepoint Ops LLC raised its stake in PDS Biotechnology by 116.1% in the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after purchasing an additional 156,662 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in PDS Biotechnology by 117.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock worth $151,000 after purchasing an additional 106,300 shares during the period. Susquehanna International Group LLP lifted its position in PDS Biotechnology by 603.7% during the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after purchasing an additional 80,937 shares during the period. Finally, Jane Street Group LLC acquired a new stake in PDS Biotechnology during the second quarter worth about $92,000. 26.84% of the stock is currently owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.